Advertisement
News
Advertisement

Repligen's SMA treatment gets fast track designation

Thu, 06/23/2011 - 9:46am
Mass High Tech: The Journal of New England Technology

Waltham biotech Repligen Corp. (Nasdaq: RGEN) has received U.S. Food and Drug Administration Fast Track designation for RG3039, a potential treatment for Spinal Muscular Atrophy (SMA), according to a press release issued by the company.

That designation is designed to expedite the review of drugs that treat serious diseases and fill an unmet medical need.

SOURCE

Advertisement

Share this Story

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading